Clinical observation on diammonium glycyrrhizinate combined with huaier granule in the treatment of embolism syndrome after TACE therapy on hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5782.2016.04.003

Abstract

Abstract:

Objective:

To investigate the clinical effect of diammonium glycyrrhizinate combined with huaier granule in the treatment of embolism syndrome after transcatheter arterial chemoembolization (TACE) therapy on hepatocellular carcinoma.

Methods:

90 patients with hepatocellular carcinoma treated by TACE were randomly divided into two groups: the observation group (45 cases) and the control group (45 cases). The control group was injected with diammonium glycyrrhizinate and the observation group was given oral intake of huaier granule in addition to diammonium glycyrrhizinate injection for a month. Following that, the transaminase and remission rate of embolism syndrome were observed to compare the clinical effect of both therapies between the two groups.

Results:

The remission rate of embolism syndrome, total effective rate and the life quality of the observation group were significantly higher than that of the control group(P<0.05). However, there was no significant difference in lowering l transaminase of patients in both groups (P>0.05).

Conclusions:

Diammonium glycyrrhizinate combined with huaier granule had significant clinical effect in the treatment of embolism syndrome after TACE therapy. It is safe and can improve the patient’s life quality, and thus is worthy of clinical application.

Key words: Hepatic carcinoma, Diammonium glycyrrhizinate, Huaier granule, TACE, Embolism syndrome

Huigang Feng, Qiwei Liang, Huizhuang Guo, Weizhao Zhuang, Chen Huang, Ying Tang, Chaoxiong He, Yi Huang. Clinical observation on diammonium glycyrrhizinate combined with huaier granule in the treatment of embolism syndrome after TACE therapy on hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2016, 04(04): 197-201.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2016.04.003

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2016/V04/I04/197

Figures/Tables 7

References 20

1	中国抗癌协会肝癌专业委员会. 原发性肝癌规范化诊治专家共识[J]. 临床肿瘤学杂志, 2009, 14(3):259-269.
2	汤钊猷. 现代肿瘤学[M]. 2版. 上海：复旦大学出版社，2003：737-738.
3	中华医学会放射学分会介入学组协作组. 原发性肝细胞癌经导管肝动脉化疗性栓塞治疗技术操作规范专家共识[J].中华放射学杂志.2011,45(10):908-912. doi:10.3760/cma.j.issn.1005-1201.2011.10.003.
4	Lin MT, Chang KC, Tseng PL, et al. The validation of 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area[J]. J Gastroenterol Hepatol，2015，30(2):345-351. doi: 10.1111/jgh.12699.
5	中国中医药学会内科肝病专业委员会. 病毒性肝炎中医疗效判定标准（试行）[J]. 中医杂志，1992, 5:53.
6	Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoemboliza-tion for hepatocellular carcinoma:single-blind, randomized trial[J]. J Natl Cancer Inst，2013,105(1):59-68. doi: 10.1093/jnci/djs464.
7	Kawamura Y, Ikeda K, Fukushima T, et al. What is the most effective drug delivery system for cisplatinduring the treatment of hepatic tumors with single-session transcatheter chemotherapy？a pilot study[J]. Gut Liver，2013,7(5):576 -584. doi: 10.5009/gnl.2013.7.5.576.
8	Brown DB，Cardella JF，Sacks D，et al. Quality improvement guidelines for transhepatic arterial chemoembolization,embolization, and chemotherapeutic infusion for hepatic malignancy[J]. J Vasc Interv Radiol，2006，17(2 Pt 1):225-232 .doi: 10.1097/01.RVI.0000195330.47954.48
9	刘峰. 异甘草酸镁治疗抗结核药物所致药物性肝炎的疗效观察[J]. 实用心脑肺血管病杂志，2010，18(6):471. doi:10.3969/j.issn.1008-5971.2010.06.067.
10	杨超君. 甘草酸18H差向异构体对急性肝损伤小鼠血清IL-2和TNF-α的影响[J]. 中国中医药科技, 2016, 23(1):43-44.
11	邵健. 异甘草酸镁注射液治疗慢性乙型肝炎的临床观察[J]. 中国医药指南，2014，26:259-260.
12	吴成久.复方甘草酸苷对慢性乙型肝炎的疗效观察[J]. 中国现代医药杂志，2012，14(10):25-27.doi:10.3969/j.issn.1672-9463.2012.10.008.
13	陈玉强, 洪节约, 张雅雅,等. 异甘草酸镁治疗肝癌动脉栓塞化疗肝损伤的临床研究[J]. 实用临床医药杂志, 2010, 14(17X):15-17. doi:10.3969/j.issn.1672-2353.2010.17.005.
14	庄毅. 抗癌新药槐耳冲剂的研究[J]. 中国药学杂志，1998, 33(5):273-275.
15	庄毅. 真菌抗癌药物槐耳颗粒的研制[J]. 中国肿瘤，1999, 12:540-543.
16	中国人民解放军第二军医大学东方肝胆医院. 槐耳冲剂治疗275例原发性肝癌的临床观察[J]. 上海中医药杂志, 1995, 3:30-31.
17	蒋梅, 周岱翰. 槐耳冲剂治疗中晚期原发性肝癌98例[J]. 上海中医药杂志, 2004, 38(6):21-22.
18	程若川,王建忠.槐耳的研制及临床应用[J]. 昆明医学院学报, 2003, 24(1):106-108
19	汪平, 仲炜, 唐成武,等. 槐耳颗粒对肝癌栓塞化疗后免疫功能的影响[J]. 中国现代医生, 2013, 51(36):58-60.
20	李敬东, 彭勇, 戴毅,等. 槐耳颗粒联合肝动脉灌注化疗栓塞治疗晚期肝癌的临床研究[J]. 西部医学, 2010, 22(3):418-420. doi:10.3969/j.issn.1672-3511.2010.03.009.

指标		观察组（n=45）	对照组（n=45）	t或χ²值	P值
年龄（岁）		56.06±10.51	55.47±11.52	0.373	0.70
性别		?	?	0.104	0.748
?	男	39	40	?	?
?	女	6	5	?	?
肝炎病毒感染		?	?	0.653	0.419
?	有	35	38	?	?
?	无	10	7	?	?
肝硬化程度		?	?	0.505	0.777
?	无	3	2	?	?
?	中度以下	20	23	?	?
?	中度及以上	22	20	?	?
肿瘤平均大小（cm）		5.03±2.32	5.30±2.76	0.502	0.617
癌栓		?	?	1.047	0.306
?	有	3	1	?	?
?	无	42	44	?	?
Child-Pugh分级		?	?	0.123	0.725
?	A级	40	41	?	?
?	B级	5	4	?	?
临床分期		?	?	0.202	0.977
?	Ⅰ期	25	27	?	?
?	Ⅱ期	17	15	?	?
?	Ⅲ期	2	2	?	?
?	Ⅳ期	1	1	?	?
病理类型		?	?	0.715	0.699
?	肝细胞肝癌	42	40	?	?
?	胆管细胞癌	1	1	?	?
?	混合型肝癌	2	4	?	?

指标		观察组（n=45）	对照组（n=45）	t或χ²值	P值
年龄（岁）		56.06±10.51	55.47±11.52	0.373	0.70
性别		?	?	0.104	0.748
?	男	39	40	?	?
?	女	6	5	?	?
肝炎病毒感染		?	?	0.653	0.419
?	有	35	38	?	?
?	无	10	7	?	?
肝硬化程度		?	?	0.505	0.777
?	无	3	2	?	?
?	中度以下	20	23	?	?
?	中度及以上	22	20	?	?
肿瘤平均大小（cm）		5.03±2.32	5.30±2.76	0.502	0.617
癌栓		?	?	1.047	0.306
?	有	3	1	?	?
?	无	42	44	?	?
Child-Pugh分级		?	?	0.123	0.725
?	A级	40	41	?	?
?	B级	5	4	?	?
临床分期		?	?	0.202	0.977
?	Ⅰ期	25	27	?	?
?	Ⅱ期	17	15	?	?
?	Ⅲ期	2	2	?	?
?	Ⅳ期	1	1	?	?
病理类型		?	?	0.715	0.699
?	肝细胞肝癌	42	40	?	?
?	胆管细胞癌	1	1	?	?
?	混合型肝癌	2	4	?	?

组别	显效	有效	无效	χ²值	P值
观察组	21	19	5	4.667	0.097
对照组	15	17	13	?	?

组别	显效	有效	无效	χ²值	P值
观察组	21	19	5	4.667	0.097
对照组	15	17	13	?	?

组别	0度	Ⅰ度	Ⅱ度	Ⅲ度	Ⅳ度	χ²值	P值
观察组	10	15	10	6	4	10.803	0.029
对照组	4	6	19	11	5	?	?

Please choose a citation manager

Content to export